LifeSciBench: A New Benchmark That Actually Tests AI on Real Biology Work

OpenAI just dropped LifeSciBench, and it’s the kind of benchmark I wish we’d seen years ago.

Most AI benchmarks in biology are a joke. They test whether a model can recall that DNA is a double helix or list the steps of the Krebs cycle. That’s not science—that’s flashcards. LifeSciBench takes a different approach. It’s built by domain experts, reviewed by domain experts, and designed to measure how well AI systems handle real-world research tasks.

What does that mean in practice? Instead of asking “What is the function of p53?”, LifeSciBench might present a messy dataset and ask the model to interpret the results, or give it a partially completed experimental design and ask what controls are missing. These are the kinds of decisions researchers make every day, and they’re exactly the kind of thing that separates a useful AI assistant from a glorified search engine.

The benchmark covers multiple subfields: molecular biology, drug discovery, clinical trial design, and bioinformatics. Each task was authored by someone with actual lab experience, then reviewed by another expert to catch errors or ambiguities. That peer-review layer is rare in AI benchmarks and frankly overdue. Too many benchmarks get released with obvious flaws that anyone in the field would spot immediately.

I’m particularly interested in the drug discovery tasks. We’ve seen a flood of papers claiming AI can design new molecules or predict drug-target interactions, but most evaluations use simplified datasets that don’t reflect real-world constraints like toxicity, solubility, or synthesis feasibility. LifeSciBench apparently includes tasks that force models to account for these factors. If it holds up, this could be a much more honest measure of where AI actually stands in drug development.

Of course, no benchmark is perfect. The sample size of tasks matters, and I’d want to see how the scoring works across different models. OpenAI hasn’t released full results yet, just the benchmark itself and some baseline numbers from GPT-4 and GPT-4o. Unsurprisingly, their own models do well—but they also published results from Claude 3.5 Sonnet and Gemini 1.5 Pro, which is more transparency than most companies offer.

The real test will be whether the research community adopts this as a standard. Benchmarks are only useful if people actually use them. LifeSciBench is open-source, so anyone can run evaluations. That’s a good start.

I’m cautiously optimistic. This feels like a step toward evaluating AI on substance rather than surface-level knowledge. If you’re building AI tools for biology or drug discovery, LifeSciBench is worth a look.